top of page

A Guide Based on AUA Recommendations

 

Uroflowmetry is a simple, non-invasive diagnostic tool that offers critical insights into a patient’s urinary flow dynamics. As endorsed by the American Urological Association (AUA), clinicians should consider uroflowmetry prior to any intervention for lower urinary tract symptoms (LUTS) or benign prostatic hyperplasia (BPH) as a Clinical Principle.

Beyond measuring flow rates, uroflowmetry provides additional diagnostic value by analyzing the shape of the flow curve and the duration of voiding. These parameters serve as effective screening tools for LUTS, helping to characterize voiding dysfunction. This data is invaluable in counseling patients about surgical outcomes and setting realistic expectations.

 

If surgical intervention becomes necessary, uroflowmetry offers a reliable method to compare pre- and post-operative flow rates. These comparisons provide objective measures of treatment outcomes, enabling clinicians to assess the success of therapy in reducing obstruction and improving patient quality of life.

Below is an overview of how the American Urological Association (AUA) recommends its use across various urological conditions:

Benign Prostatic Hyperplasia (BPH)

For patients with lower urinary tract symptoms (LUTS) suggestive of BPH

  • Uroflowmetry is recommended as part of the initial diagnostic workup.

  • It helps quantify urine flow rates, aiding in the assessment of potential bladder outlet obstruction.

  • As an office-based procedure, it complements patient history and other diagnostic measures.

 

Urethral Stricture

In men presenting with symptoms like reduced urinary stream or incomplete bladder emptying

  • Uroflowmetry can assist in diagnosing urethral stricture.

  • The AUA emphasizes using uroflowmetry alongside patient-reported measures and post-void residual (PVR) volume assessment for a comprehensive evaluation.

Neurogenic Lower Urinary Tract Dysfunction (NLUTD)

In patients with suspected NLUTD

  • Uroflowmetry offers insights into voiding function but is not sufficient to exclude significant underlying abnormalities.

  • The AUA advises targeted use in cases with specific clinical indications, often as part of a broader urodynamic evaluation.

bottom of page